You need Flash Player 8 to view this movie.

Robert Pawlak, MD-PhD

 

Lecturer in Neuroscience, University of Leicester, UK

 

Education:

1994 Diploma of Physician, Faculty of Medicine, Medical University of Bialystok, Poland

1997 PhD, Medical University of Bialystok, Poland
 

Professional experience:

2005 - to date Department of Cell Physiology and Pharmacology, University of Leicester, UK
                      Lecturer in Neuroscience

2001 - 2006     Laboratory of Neurobiology and Genetics, Rockefeller University, New York, USA
                      Postdoctoral Associate and Adjunct Member of the Faculty

1998 - 2000     Department of Physiology, Hamamatsu University School of Medicine, Japan
                      Postdoctoral Fellowship of the Ministry of Education, Science and Culture of Japan

1995 - 1998     Department of Pharmacodynamics, Medical University of Bialystok, Poland
                      Researcher 

 

Awards and Honors:

2007 Marie Curie Excellence Grant, European Commission

2002 Young Investigator Award, 2 nd Asia-Pacific Congress of Thromb. & Hemost., Seoul, Korea

2000 The Award for Excellence in Research from the Ministry of Health of Poland

2000 The Young Investigator Award, XVth ICFP, Hamamatsu, Japan

1998 The Award for Excellence in Research from the Ministry of Health of Poland

 

Publications:

  1. Bennur S, B.S. Shankaranarayana Rao, Pawlak R, Strickland S, McEwen BS, Chattarji S . Stress-induced spine loss in the medial amygdala is mediated by tissue-plasminogen activator. Neuroscience 2007, 144(1):8-16.
  2. Pawlak R ­­­­­­ , B.S.Shankaranarayana Rao, Melchor JP, Chattarji S, McEwen B, Strickland S. Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci U S A 2005, 112(50): 18201-18206.
  3. Pawlak, R ., Melchor, J.P., Matys, T., Skrzypiec, A.E. & Strickland, S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S A 2005, 102(2), 443-448.
  4. Matys T, Pawlak R, Strickland S: Tissue plasminogen activator in the bed nucleus of stria terminalis regulates acoustic startle. Neuroscience 2005, 135(3):715-722
  5. Mogielnicki A , Chabielska E , Pawlak R , Szemraj J , Buczko W . Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost. 2005, 93(6):1069-1076.
  6. * Matys T, * Pawlak R, Matys E, Pavlides C, McEwen BS, Strickland S: Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. Proc Natl Acad Sci U S A 2004, 101(46), 16345-16350. * Co-first authors.
  7. Pawlak R , Magarinos AM, Melchor JP, McEwen B, Strickland S: Tissue-plasminogen activator in the amygdala is critical for anxiety-like behavior. Nature Neuroscience 2003, 6( 2): 168- 174
  8. Melchor J.P, Pawlak R, Strickland S: The tPA/plasminogen proteolytic cascade accelerates Aß degradation and inhibits Aß-induced neurodegeneration. J Neurosci 2003, 23( 26): 8867-8871
  9. Melchor JP, Pawlak R , Chen Z, Strickland S. The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer's disease. J Mol Neurosci. 2003, 20(3):287-289.
  10. Matys T, Kucharewicz I, Pawlak R, Chabielska E, Domaniewski T, Buczko W. Nitric oxide-dependent antiplatelet action of AT 1-receptor antagonists in a pulmonary thromboembolism in mice. J Cardiovasc Pharmacol 2003, 42(6):710-713.
  11. Pawlak R , Strickland S: Tissue plasminogen activator and seizures – a clot-buster’s secret life. Journal of Clinical Investigation, 2002, 109( 12): 1529-1531
  12. Pawlak R , Skrzypiec A, Sulkowski S, Buczko W. Ethanol-induced neurotoxicity is counterbalanced by increased cell proliferation in mouse dentate gyrus.
    Neurosci Lett . 2002, 327(2):83-6.
  13. Pawlak ­ R , Nagai N, Urano T, Napiorkowska-Pawlak D, Ihara H, Takada Y, Collen D, Takada A: Rapid, specific and active site-catalyzed effect of tissue-plasminogen activator on hippocampus-dependent learning in mice. Neuroscience, 2002, 113( 4): 995-1001
  14. Kucharewicz I, Pawlak R, Matys T, Pawlak D, Buczko W: Antithrombotic effect of captopril and losartan is mediated by angiotensin-( 1- 7). Hypertension 2002, 40( 5): 774- 779
  15. Kucharewicz I, Pawlak R, Matys T, Chabielska E, Buczko W. Angiotensin-( 1- 7): an active member of the renin-angiotensin system. J Physiol Pharmacol 2002 Dec; 53( 4 Pt 1): 533- 540
  16. Sakata K, Pawlak R, Urano T, Takada A: Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension. Pathophysiol Haemost Thromb 2002, 32( 2): 67- 75
  17. Zoltowski R, Pawlak R, Matys T, Pietraszek M, Buczko W: Propranolol modifies platelet serotonergic mechanisms in rats. J Physiol Pharmacol 2002, 53( 2): 265- 274
  18. Pawlak R , Napiorkowska-Pawlak D, Takada Y, Urano T, Nagai N, Ihara H, Takada A.The differential effect of angiotensin II and angiotensin 1-7 on norepinephrine, epinephrine, and dopamine concentrations in rat hypothalamus: the involvement of angiotensin receptors. Brain Res Bull. 2001, 54(6):689-94.
  19. Buczko W, Matys T, Pawlak R, Kucharewicz I, Chabielska E. Studies on the antithrombotic action of AT 1 receptor antagonists. Med Sci Monit 2001; 7( 4): 600- 605
  20. Gruszecki M, Rółkowski R, Pawlak R, Buczko W:Propranolol prevents the development of venous thrombosis in rats by a platelet-dependent mechanism. Pol J Pharmacol 2001, 53: 5- 10
  21. Matys T, Chabielska E, Pawlak R, Kucharewicz I, Buczko W: Losartan inhibits the adhesion of rat platelets to fibrillar collagen--a potential role of nitric oxide and prostanoids. J Physiol Pharmacol 2000 Dec; 51( 4 Pt 1): 705- 713
  22. Napiorkowska-Pawlak D, Malinowska B, Pawlak R , Buczko W, Gothert M.Attenuation of the acute amnestic effect of ethanol by ifenprodil: comparison with ondansetron and dizocilpine. Fundam Clin Pharmacol. 2000, 14(2):125-31.
  23. Minowa K, Pawlak R , Takada Y, Takada A. Nicotine attenuates stress-induced changes in plasma amino acid concentrations and locomotor activity in rats. Brain Res Bull. 2000, 51(1):83-8.
  24. Pawlak R , Takada Y, Takahashi H, Urano T, Ihara H, Nagai N, Takada A. Differential effects of nicotine against stress-induced changes in dopaminergic system in rat striatum and hippocampus. Eur J Pharmacol. 2000, 387(2):171-7.
  25. Pawlak R , Chabielska E, Matys T, Kucharewicz I, Rółkowski R, Buczko W. Thiol repletion prevents venous thrombosis in rats by nitric oxide/prostacyclin-dependent mechanism: relation to the antithrombotic action of captopril. J Cardiovasc Pharmacol 2000 , 34( 4): 503- 509
  26. Pawlak R , Chabielska E, Matys T, Kucharewicz I, Buczko W. The role of thiol group in the antithrombotic action of captopril. Thromb Haemost 2000 , 84: 919- 920
  27. Matys T, Pawlak R, Kucharewicz I, Chabielska E, Buczko W. Hypotensive effect of angiotensin II after AT 1-receptor blockade with losartan. J Physiol Pharmacol 2000 Mar; 51( 1): 161- 166
  28. Azzadin A, Wollny T, Pawlak R, Malyszko JS, Malyszko J, Mysliwiec M, Buczko W. L-Carnitine effects on anemia in uremic rats treated with erythropoietin. Nephron 1999 ; 83( 4): 370- 371
  29. Chabielska E, Pawlak R, Wollny T, Rolkowski R, Buczko W. Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action. J Physiol Pharmacol 1999, 50( 1): 99- 109
  30. Malinowska B, Napiorkowska-Pawlak D, Pawlak R , Buczko W, Gothert M. Ifenprodil influences changes in mouse behaviour related to acute and chronic ethanol administration. Eur J Pharmacol. 1999, 377(1):13-9.
  31. Chabielska E, Pawlak R, Golatowski J, Rolkowski R, Pawlak D, Buczko W. Losartan inhibits experimental venous thrombosis in spontaneously hypertensive rats. Thromb Res 1998, 90( 6): 271- 278
  32. Chabielska E, Pawlak R, Golatowski J, Buczko W. The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats. J Physiol Pharmacol 1998, 49( 2): 251- 260
  33. Pawlak R , Chabielska E, Golatowski J, Azzadin A, Buczko W. Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats. Thromb Haemost 1998, 79( 6): 1208- 1212
  34. Buczko W, Pawlak R, Chabielska E, Azzadin A, Famulski W. Cardiac side effects of L-NMMA. Crit Care Med 1998 , 26( 1): 189- 191
  35. Krygicz D, Azzadin A, Pawlak R , Malyszko JS, Pawlak D, Mysliwiec M, Buczko W. Cyclosporine A affects serotonergic mechanisms in uremic rats.
    Pol J Pharmacol. 1996, 48(3):351-4.
  36. Pietraszek M, Chabielska E, Azzadin A, Pawlak R , Buczko W. Effect of endothelin-1 on some hemostatic parameters in normotensive rats. Acta Physiol Hung. 1996, 84(3):329-30.
  37. Pawlak R , Chabielska E, Rolkowski R, Buczko W. Influence of captopril on some haemostatic parameters in rats with ongoing process of venous thrombosis. Acta Physiol Hung. 1996, 84(3):327-8.
  38. Chabielska E, Pawlak R , Buczko W. Losartan does not influence the blood platelet aggregation in normotensive rats. Acta Physiol Hung. 1996, 84(3):271-2.
  39. Pawlak R , Chabielska E, Buczko W. Antithrombotic effect of enalapril, an angiotensin-converting enzyme inhibitor, on venous thrombosis in rats. Pol J Pharmacol. 1996, 48(1):117-20.
  40. Chabielska E, Pawlak R , Buczko W. Effects of drugs affecting the renin-angiotensin system on venous thrombosis in normotensive rats. Pol J Pharmacol. 1996, 48(1):89-91.
  41. Chabielska E, Pawlak R . Losartan, new angiotensin receptor antagonist - a challenge for angiotensin converting enzyme inhibitors?
    Wiad Lek. 1995, 48(1-12):242-245.